<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A multicentre phase II trial was conducted to evaluate the efficacy and toxicity of <z:chebi fb="0" ids="175901">gemcitabine</z:chebi> in patients with refractory or relapsed indolent non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty-six patients were enrolled onto the study, including 11 cases of mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>), 10 cases of <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (CLL)/lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, nine cases of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, four cases of lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and two cases of T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="175901">Gemcitabine</z:chebi> 1 g/m(2) was administered as a 30-min infusion on d 1, 8 and 15 of a 28-d schedule, up to a maximum of six cycles </plain></SENT>
<SENT sid="3" pm="."><plain>Complete responses were observed in two patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>, and partial responses were observed in seven patients, including three patients with CLL/lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, two patients with T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, one patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> and one patient with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Minor responses were observed in three patients, including two patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> and one patient with CLL </plain></SENT>
<SENT sid="5" pm="."><plain>The median duration of response was 150 d and the overall progression-free survival was 342 d </plain></SENT>
<SENT sid="6" pm="."><plain>Haematological toxicity was observed as grade 3-4 leucopenia in 12 patients (33%) and grade 3-4 <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> in 18 patients (50%) </plain></SENT>
<SENT sid="7" pm="."><plain>Severe non-haematological toxicity included one case of fatal <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">veno-occlusive disease</z:e>, one case of <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e> leading to terminal <z:hpo ids='HP_0000083'>renal failure</z:hpo>, one case of <z:e sem="disease" ids="C0343084" disease_type="Disease or Syndrome" abbrv="AVLS">capillary leak syndrome</z:e>, one case of <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> and drug-induced <z:hpo ids='HP_0001945'>fever</z:hpo> in two patients </plain></SENT>
<SENT sid="8" pm="."><plain>These data suggest that <z:chebi fb="0" ids="175901">gemcitabine</z:chebi> displays activity in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> and CLL/lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Haematological toxicity was frequent in these heavily treated patients </plain></SENT>
<SENT sid="10" pm="."><plain>Severe non-haematological toxicity was significant and should be taken into account in the design of future trials </plain></SENT>
</text></document>